A detailed history of Envestnet Asset Management Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 11,509 shares of KRYS stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,509
Previous 7,008 64.23%
Holding current value
$1.97 Million
Previous $1.29 Million 62.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$174.7 - $213.66 $786,324 - $961,683
4,501 Added 64.23%
11,509 $2.09 Million
Q2 2024

Aug 08, 2024

BUY
$153.12 - $183.64 $388,159 - $465,527
2,535 Added 56.67%
7,008 $1.29 Million
Q1 2024

May 13, 2024

BUY
$108.01 - $179.35 $198,846 - $330,183
1,841 Added 69.95%
4,473 $795,000
Q4 2023

Feb 13, 2024

SELL
$96.0 - $128.29 $96,576 - $129,059
-1,006 Reduced 27.65%
2,632 $326,000
Q3 2023

Nov 13, 2023

BUY
$108.51 - $130.22 $394,759 - $473,740
3,638 New
3,638 $422,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.38B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.